Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study

Rosti, Gianantonio; Hochhaus, Andreas; Gambacorti-Passerini, Carlo; Kuttschreuter, Luke; Giraldo-Castellano, Pilar; Zhao, Huadong; Castagnetti, Fausto; Giles, Francis J.; Ernst, Thomas; Purcell, Simon; Brümmendorf, Tim Henrik; Gjertsen, Björn T.

doi:10.18154/RWTH-CONV-252649

%0 Journal Article
%A Rosti, Gianantonio
%A Brümmendorf, Tim Henrik
%A Gjertsen, Björn T.
%A Giraldo-Castellano, Pilar
%A Castagnetti, Fausto
%A Gambacorti-Passerini, Carlo
%A Ernst, Thomas
%A Zhao, Huadong
%A Kuttschreuter, Luke
%A Purcell, Simon
%A Giles, Francis J.
%A Hochhaus, Andreas
%T Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study
%J Leukemia : normal and malignant hemopoiesis
%V 38
%N 1
%@ 1476-5551
%C London
%I Springer Nature
%M RWTH-CONV-252649
%P 126-135
%D 2024
%Z Published: 25 November 2023
%F PUB:(DE-HGF)16
%9 Journal Article
%U <Go to ISI:>//WOS:001109383900001
%$ pmid:38007586
%R 10.1038/s41375-023-02080-y
%U https://publications.rwth-aachen.de/record/982586

h1

h2

h3

h4

h5

h6

RWTH

Kontakt

RWTH Publications

Allgemeines